CEO Hanna Sjöström presented GPX Medical at Life Science Day in Gothenburg March 4th to 140 Swedish life science investors.

GPX Medical has set the foundation for commercialization of a new unique medical device for lung monitoring of preterm born infants with great potential on the Global market for neonatal care. The market potential is substantial, one out of ten infants are born preterm.

GPX Medical’s medical device, Neola, targets preterm born infants with respiratory problems. The company has had promising results from three studies with 32 newborns.

-We are planning for a CE-marked Neola in 2023, says Hanna Sjöström. The company has a parallell process with FDA to be able to sell in the U.S.

About GPX Medical

GPX Medical AB was formed in 2016 as a subsidiary to Gasporox AB (publ) with the aim to develop and commercialize medical applications of the GASMAS technology. The company is owned by Gasporox AB (publ) to 53,3%, by Norsk Elektro Optikk AS to 36,2% and by the team to 10,5%. The company is located in Lund, Sweden. Org. nbr. 559069-9012.

For investors

Please contact CEO Hanna Sjöström for investment opportunities:
hs@gpxmedical.se

Contact

GPX Medical AB
Tellusgatan 13
224 57 Lund
Sweden
info@gpxmedical.se